Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Feeling deeply grateful for the overwhelming response to our recent American Society of Clinical Oncology (ASCO) Flagship journal JCO commentary:
“Precision Oncology and Modernizing Evidence Standards.”
The flood of texts/ DM’s/ and email messages from leaders across industry, academia, and policy underscores how widely this call for modernized evidence resonates.
Thank you to the ASCO & Journal of Clinical Oncology for publishing our piece and amplifying the urgency.”
Title: Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review
Authors: Vivek Subbiah, Razelle Kurzrock
Read the Full Article.
